Spots Global Cancer Trial Database for brentuximab vedotin
Every month we try and update this database with for brentuximab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | NCT05404945 | Classical Hodgk... | Pembrolizumab Doxorubicin Vinblastine Dacarbazine Brentuximab ved... | 60 Years - | University of Virginia | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | NCT04404283 | Diffuse Large B... | Brentuximab ved... Rituximab Lenalidomide Placebo | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT03013933 | Recurrent Hodgk... Refractory Hodg... | Brentuximab Ved... Cyclosporine Pharmacokinetic... Verapamil Verapamil Hydro... | 15 Years - | City of Hope Medical Center | |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | NCT03719105 | NK-Cell Lymphom... NK-Cell Leukemi... Peripheral T Ce... | Methotrexate pralatraxate, Ifosfamide Dexamethasone Etoposide calaspargase pe... cyclophosphamid... Doxorubicin Prednisone Brentuximab Ved... | 1 Year - 31 Years | New York Medical College | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | NCT05357794 | Mycosis Fungoid... | Brentuximab ved... | 18 Years - | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | NCT05039073 | Recurrent Class... Refractory Clas... | Brentuximab Ved... Hematopoietic C... Nivolumab Quality-of-Life... Questionnaire A... | 12 Years - | Emory University | |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | NCT04609566 | Melanoma Non-small Cell ... Squamous Cell C... | brentuximab ved... pembrolizumab | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | NCT05313243 | T-Cell Lymphoma | Brentuximab ved... Pembrolizumab | 18 Years - | Yale University | |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | NCT02098512 | Hodgkin Lymphom... | Brentuximab Ved... Allogeneic Stem... Reduced Intensi... | - 45 Years | New York Medical College | |
| A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | NCT02616965 | Cutaneous T-cel... | Romidepsin Brentuximab ved... | 18 Years - | Fox Chase Cancer Center | |
| Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients | NCT01994850 | CD30 Positive P... CD30-Positive D... CD30-Positive G... | brentuximab ved... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | NCT03587844 | Mycosis Fungoid... Lymphomatoid Pa... Sezary Syndrome | brentuximab ved... brentuximab ved... brentuximab ved... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | NCT02275598 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 8 Years - 70 Years | University of Modena and Reggio Emilia | |
| Brentuximab for Newly Diagnosed Hodgkin Disease | NCT02398240 | Hodgkin Lymphom... | Brentuximab Ved... Doxorubicin Vincristine Rituximab | 1 Year - 29 Years | New York Medical College | |
| Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL | NCT02462538 | ALK+ Anaplastic... | Brentuximab ved... Imatinib | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | NCT02686346 | Hodgkin Disease | Brentuximab Ved... Etoposide Carboplatine Ifosfamide | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| CD30 Imaging in Diffuse Large B-cell Lymphoma | NCT06186986 | Diffuse Large B... | Brentuximab ved... | 18 Years - 75 Years | University Medical Center Groningen | |
| Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | NCT03496779 | Refractory Peri... Relapsed Periph... | Brentuximab Ved... Gemcitabine Brentuximab Ved... autologous or a... | 18 Years - 80 Years | The Lymphoma Academic Research Organisation | |
| TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | NCT02822586 | Mycosis Fungoid... Sézary Syndrome | TSEB Therapy Brentuximab ved... | 18 Years - | Virginia Commonwealth University | |
| A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma | NCT02572167 | Hodgkin Lymphom... | brentuximab ved... nivolumab | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | NCT03712202 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... Lymphocyte-Rich... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Bleomycin Brentuximab Ved... Dacarbazine Doxorubicin Nivolumab Quality-of-Life... Vinblastine | 16 Years - | City of Hope Medical Center | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas | NCT02581631 | Non-Hodgkin's D... | Nivolumab Brentuximab Ved... | 15 Years - | Bristol-Myers Squibb | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | NCT01771107 | AIDS-Related Ho... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... HIV Infection | Brentuximab Ved... Dacarbazine Doxorubicin Hyd... Pharmacological... Vinblastine | 18 Years - | National Cancer Institute (NCI) | |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02254239 | Recurrent Hodgk... Refractory Hodg... | Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02086604 | Lymphoma, Large... | Brentuximab ved... Lenalidomide | 18 Years - | Washington University School of Medicine | |
| Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors | NCT01851200 | Germ Cell Cance... | Brentuximab Ved... | 18 Years - | Fondazione Michelangelo | |
| Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery | NCT03007030 | CD30-Positive N... Malignant Mesot... | Brentuximab Ved... Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse | NCT03356054 | DLBCL | R-DHAP Brentuximab Ved... | 18 Years - | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma | NCT05922904 | Hodgkin Lymphom... | Brentuximab ved... Doxorubicin Hyd... Pembrolizumab Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | NCT04795869 | Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Nodal... Recurrent Perip... Recurrent Subcu... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Noda... Refractory Peri... Refractory Subc... | Brentuximab Ved... Pembrolizumab | 18 Years - | Northwestern University | |
| Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | NCT02408042 | Lymphoma Hodgkin's Lymph... Non-hodgkin's L... | Pembrolizumab Etoposide Ifosfamide Mesna Carboplatin Brentuximab ved... Rituximab | 18 Years - | Western Regional Medical Center | |
| Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | NCT01534078 | Hodgkin Lymphom... | Brentuximab Ved... Adriamycin, vin... | 18 Years - | Massachusetts General Hospital | |
| A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity | NCT02567851 | Hodgkin Disease | Brentuximab Ved... | 16 Years - | University of Birmingham | |
| Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02254239 | Recurrent Hodgk... Refractory Hodg... | Brentuximab Ved... Everolimus Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | NCT01026415 | Carcinomas Disease, Hodgki... Lymphoma, Large... Lymphoma, Non-H... Neoplasms | brentuximab ved... rifampin midazolam ketoconazole brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) | NCT01578499 | Primary Cutaneo... Mycosis Fungoid... Cutaneous T-Cel... | Brentuximab Ved... Methotrexate Bexarotene | 18 Years - | Takeda | |
| Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides | NCT05357794 | Mycosis Fungoid... | Brentuximab ved... | 18 Years - | M.D. Anderson Cancer Center | |
| Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | NCT03233347 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Classic Hodgkin... | Brentuximab Ved... Dacarbazine Doxorubicin Laboratory Biom... Nivolumab Vinblastine | 18 Years - 60 Years | Academic and Community Cancer Research United | |
| Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | NCT03517137 | Advanced Hodgki... | Brentuximab Ved... Adriamycin Vinblastine Dacarbazine Etoposide Cyclophosphamid... Radiation Thera... | 18 Years - 60 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | NCT03409432 | Lymphomatoid Pa... Primary Cutaneo... Recurrent Prima... Recurrent T-Cel... Refractory Prim... Stage I Cutaneo... Stage II Cutane... Stage III Cutan... Stage IV Cutane... | Brentuximab Ved... Laboratory Biom... Lenalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas | NCT02280785 | Non-Hodgkin Lym... | Brentuximab ved... | 19 Years - 75 Years | Samsung Medical Center | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) | NCT05673785 | Lymphoma | Brentuximab Ved... Cyclophosphamid... Doxorubicin Prednisone | 18 Years - | Takeda | |
| Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | NCT04561206 | Relapsed Classi... | Brentuximab Ved... Nivolumab | 18 Years - | City of Hope Medical Center | |
| HD21 for Advanced Stages | NCT02661503 | Classical Hodgk... | Bleomycin Etoposide Doxorubicin Cyclophosphamid... Vincristine Procarbazine Prednisone Brentuximab Ved... Dacarbazine Dexamethasone | 18 Years - 60 Years | University of Cologne | |
| Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | NCT02298283 | Hodgkin Lymphom... | brentuximab ved... Cyclophosphamid... Adriamycin Oncovin Bleomycin Etoposide Procarbazine Prednisone G-CSF 30 Grays | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Brentuximab Vedotin + Re-induction Chemotherapy for AML | NCT01830777 | Acute Myelogeno... | Brentuximab Ved... Mitoxantrone Etoposide Cytarabine | 18 Years - | Massachusetts General Hospital | |
| PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | NCT04745949 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Brentuximab Ved... Cyclophosphamid... Doxorubicin Nivolumab Prednisone Quality-of-Life... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. | NCT03217643 | Enteropathy Ass... | Brentuximab Ved... | 18 Years - 65 Years | Imagine Institute | |
| A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) | NCT01100502 | Disease, Hodgki... | brentuximab ved... placebo | 18 Years - | Seagen Inc. | |
| A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | NCT00848926 | Disease, Hodgki... | brentuximab ved... | 12 Years - | Seagen Inc. | |
| Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | NCT04561206 | Relapsed Classi... | Brentuximab Ved... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT02227199 | Recurrent Hodgk... Refractory Hodg... | Brentuximab Ved... Carboplatin Etoposide Ifosfamide Laboratory Biom... | 18 Years - | University of Washington | |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | NCT05675410 | Lugano Classifi... | Biospecimen Col... Bleomycin Sulfa... Brentuximab Ved... Computed Tomogr... Cyclophosphamid... Dacarbazine Doxorubicin Hyd... Etoposide Etoposide Phosp... Fludeoxyglucose... Involved-site R... Magnetic Resona... Nivolumab Positron Emissi... Prednisolone Prednisone Procarbazine Hy... Questionnaire A... Vinblastine Sul... Vincristine Sul... | 5 Years - 60 Years | National Cancer Institute (NCI) | |
| Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | NCT01569204 | Hodgkin Lymphom... | Etoposide Cyclophosphamid... Doxorubicin Prednisone Procarbazine Dexamethasone Dacarbazine Brentuximab Ved... | 18 Years - 60 Years | University of Cologne | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | NCT04404283 | Diffuse Large B... | Brentuximab ved... Rituximab Lenalidomide Placebo | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | NCT02166463 | Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... Childhood Hodgk... Classic Hodgkin... | Bleomycin Sulfa... Brentuximab Ved... Cyclophosphamid... Doxorubicin Hyd... Etoposide Laboratory Biom... Methylprednisol... Pharmacological... Prednisone Quality-of-Life... Questionnaire A... Vincristine Sul... | 2 Years - 22 Years | National Cancer Institute (NCI) | |
| Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma | NCT02191930 | Hodgkin Lymphom... | B-CAP Brentuximab Ved... | 60 Years - 99 Years | University of Cologne | |
| A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL | NCT02423291 | Primary Mediast... | Brentuximab Ved... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | NCT01979536 | Anaplastic Larg... Ann Arbor Stage... Ann Arbor Stage... Ann Arbor Stage... | Brentuximab Ved... Crizotinib Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Etoposide Ifosfamide Methotrexate | - 21 Years | National Cancer Institute (NCI) | |
| Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | NCT01900496 | Lymphoma | Brentuximab ved... Rituximab | 16 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | NCT01712490 | Hodgkin Lymphom... | brentuximab ved... doxorubicin bleomycin vinblastine dacarbazine | 18 Years - | Takeda | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Brentuximab for Newly Diagnosed Hodgkin Disease | NCT02398240 | Hodgkin Lymphom... | Brentuximab Ved... Doxorubicin Vincristine Rituximab | 1 Year - 29 Years | New York Medical College | |
| Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02086604 | Lymphoma, Large... | Brentuximab ved... Lenalidomide | 18 Years - | Washington University School of Medicine | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. | |
| Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) | NCT02096042 | Leukemia | Brentuximab Ved... 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors | NCT02988843 | Germ Cell Tumor | Brentuximab Ved... Bevacizumab | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma | NCT01780662 | Recurrent Adult... Recurrent Child... Refractory Chil... | Brentuximab Ved... Gemcitabine Hyd... | 13 Months - 30 Years | National Cancer Institute (NCI) | |
| A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | NCT01060904 | Disease, Hodgki... | brentuximab ved... doxorubicin vinblastine dacarbazine bleomycin brentuximab ved... | 18 Years - 60 Years | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
